A detailed history of Engineers Gate Manager LP transactions in Insmed Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 32,557 shares of INSM stock, worth $2.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
32,557
Previous 13,174 147.13%
Holding current value
$2.1 Million
Previous $408,000 116.42%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $498,530 - $580,327
19,383 Added 147.13%
32,557 $883,000
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $593,181 - $803,910
-25,328 Reduced 65.78%
13,174 $408,000
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $764,649 - $1.04 Million
38,502 New
38,502 $972,000
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $743,260 - $993,300
45,711 New
45,711 $779,000
Q3 2022

Nov 14, 2022

BUY
$20.88 - $28.21 $639,992 - $864,664
30,651 New
30,651 $660,000
Q2 2022

Aug 15, 2022

SELL
$17.07 - $25.71 $330,799 - $498,234
-19,379 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $395,719 - $545,131
19,379 New
19,379 $455,000
Q2 2021

Aug 16, 2021

SELL
$24.17 - $36.01 $431,434 - $642,778
-17,850 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$32.28 - $44.3 $152,974 - $209,937
-4,739 Reduced 20.98%
17,850 $608,000
Q4 2020

Feb 16, 2021

BUY
$31.45 - $40.54 $509,144 - $656,302
16,189 Added 252.95%
22,589 $752,000
Q3 2020

Nov 16, 2020

BUY
$26.0 - $34.5 $166,400 - $220,800
6,400 New
6,400 $206,000
Q1 2020

May 15, 2020

SELL
$13.63 - $33.98 $456,482 - $1.14 Million
-33,491 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$16.12 - $24.98 $205,481 - $318,420
-12,747 Reduced 27.57%
33,491 $800,000
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $716,226 - $1.19 Million
46,238 New
46,238 $816,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.74B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.